Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This, combined with the interim dividend of ₹7.00 per share, brings the total dividend for FY26 to ₹9.33 per share. The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 26th AGM in 2026 until the 31st AGM in 2031, subject to shareholder approval. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. Key leadership changes were also approved. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for a further period of five years from May 04, 2027, to May 03, 2032, pending shareholder approval. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 08, 2026, subject to shareholder approval. Additionally, the Board accepted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, both effective May 07, 2026. The company also approved an investment of up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics Private Limited, to support its operations and capital requirements. The Memorandum of Association (MOA) of the company is also set for alteration to align with the Companies Act, 2013, and broaden its scope in the healthcare and diagnostics ecosystem.
